Physician profile
Erwin Manfred Korman
NPI 1225090426
$6,812.63
in general payments reported to CMS, 2019-2025
38 companies · $1,266 in 2025
The $1,266 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,786 · 2020: $212 · 2021: $903 · 2022: $773 · 2023: $1,020 · 2024: $853 · 2025: $1,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,349 · Travel and Lodging: $635 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,348.75 |
| Travel and Lodging | $634.86 |
| Education | $154.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,204.66 | 2019-2024 | |
| Abbvie INC. | $869.36 | 2019-2023 | |
| Virtual Incision Corporation | $722.81 | 2025 | Mira |
| Astellas Pharma US INC | $662.05 | 2022-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $482.02 | 2021-2025 | |
| Pfizer INC. | $414.90 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $394.06 | 2019-2025 | |
| Biogen, INC. | $335.26 | 2024-2025 | Zurzuvae |
| Medtronic, INC. | $188.01 | 2022-2025 | Ligasure, Truclear |
| Millicent US INC | $180.74 | 2020-2025 | Intrarosa, Femring, Femlyv |
| Lupin INC. | $150.50 | 2019-2021 | |
| Evofem Biosciences, INC. | $131.58 | 2021-2025 | Phexxi, Solosec, Phexx |
| Conmed Corporation | $115.49 | 2019-2021 | |
| Coopersurgical, INC. | $113.57 | 2019-2024 | Wallach Cryosurgical Equipment, Paragard T 380a |
| Hologic Sales and Service, LLC | $100.92 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $81.81 | 2021-2022 | |
| Organon LLC | $67.56 | 2021-2025 | Nexplanon |
| Davol INC. | $57.21 | 2022 | |
| Avanos Medical | $52.13 | 2019-2023 | On-Q* Pump and Accessories |
| Shield Therapeutics INC | $48.70 | 2022-2024 | |
| Amag Pharmaceuticals, INC. | $46.92 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $42.29 | 2023 | Myfembree |
| Avion Pharmaceuticals | $37.54 | 2021 | |
| Aspira Women'S Health INC | $30.68 | 2024 | Ova1 |
| Covidien LP | $29.93 | 2019 | |
| Merck Sharp & Dohme LLC | $28.52 | 2020-2021 | |
| Therapeuticsmd, INC. | $25.62 | 2019 | |
| Aroa Biosurgery Incorporated | $24.50 | 2025 | |
| Mylan Pharmaceuticals INC. | $23.83 | 2022 | |
| Acessa Health INC. | $21.70 | 2019 | |
| Smith+Nephew, INC. | $19.34 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $19.21 | 2021 | |
| Vertical Pharmaceuticals, LLC | $16.40 | 2019 | |
| Mission Pharmacal Company | $16.34 | 2023 | Citranatal |
| Exeltis, USA INC. | $15.56 | 2022 | |
| Allergan, INC. | $14.64 | 2019 | |
| Medicem INC. | $14.25 | 2020 | |
| Ascend Therapeutics US, LLC | $12.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erwin Korman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.